Theralase Technologies Inc.

Theralase Technologies Inc.

December 14, 2009 09:00 ET

Theralase Technologies Inc.: Medical Laser Inventors Announce Appointment of Marketing Consultants

TORONTO, ONTARIO--(Marketwire - Dec. 14, 2009) - Vaughn Wyant and Lori Leach have been named marketing and media relations consultants for Theralase Technologies Inc. (TSX VENTURE:TLT) Theralase develops and produces patented super-pulsed laser technology used in the healthcare sector.

By appointing Wyant and Leach, Theralase plans to capitalize on the wealth of knowledge and experience they bring to the table in marketing and media relations, as well as global product marketing.

"Vaughn and Lori add an element to the Theralase team we were missing before," said Roger Dumoulin-White, President and CEO of Theralase Technologies Inc. "We realize we're experts in medical technology and look forward to Vaughn and Lori's expertise in marketing to help us communicate our amazing product to the world outside." 

Wyant and Leach are both leaders in their respective fields. Wyant, owns and manages a 14 dealership automotive group – one of the largest in the country and is the Chairman of the Board for Great Western Brewing Company and Tricor Automotive Group. Leach is the founder of a successful creative boutique, which provides communications solutions for numerous clients in the private, public and not for profit sectors.

Wyant knows Theralase in on the cusp of something big and feels the guidance he and Lori can provide will help them attract more customers to the product and increase the brand awareness of the Company.

"When we were introduced to Theralase and asked to improve communications, it was a no brainer", says Wyant. "These guys have a great product. It has so many applications, including the potential to treat cancer, that no one has ever been able to capture with a practical, easy to use medical device. It's our job to show them how to get the word out and make it viral."

By bringing in leaders in marketing and communications, Theralase believes they have positioned themselves to attract important media and investor support to help their business thrive.

Associated with this appointment, Vaughn Wyant will receive 200,000 (TSX VENTURE:TLT) stock options and Ms. Lori Leach will receive 100,000 (TSX VENTURE:TLT) stock options exercisable for 5 years and vesting over 3 years at a strike price of $0.35.

Theralase Technologies Inc. designs, develops and manufactures patented, super-pulsed laser technology utilized in bio-stimulation and bio-destruction applications. The technology is safe and effective in the treatment of chronic pain, neural muscular skeletal conditions and wound care. When combined with patented light-sensitive Photo Dynamic Compounds, Theralase laser technology is able to specifically target and destroy cancers, bacteria and viruses.

Visit and click on the 'Investor Relations' icon for the latest news and developments surrounding the company.

This press release contains forward-looking statements which reflect the Company's current expectations regarding future events. The forward-looking statements involve risks and uncertainties. Actual results could differ materially from those projected herein. The Company disclaims any obligation to update these forward-looking statements

The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of the contents of this release.

Contact Information